Grzegorz Węgrzyn

Dr. Grzegorz Węgrzyn

Depratment of Molecular Biology, University of Gdańsk, Wita Stwosza 59, 80-308 Gdańsk, Poland
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2021 in FEMS Microbiology Reviews
Verified
Journal Article
Open access
PDF file
WJWeronika Jaroszewicz
Weronika Jaroszewicz
JMJoanna Morcinek-Orłowska
Joanna Morcinek-Orłowska
Karolina PierzynowskaKarolina Pierzynowska
Karolina Pierzynowska
LGLidia Gaffke
Lidia Gaffke
Grzegorz WęgrzynGrzegorz Węgrzyn
Grzegorz Węgrzyn
Phage display technology, which is based on the presentation of peptide sequences on the surface of bacteriophage virions, was developed over 30 years ago. Improvements in phage display systems have allowed us to employ this method in numerous fields of biotechnology, as diverse as immunological and biomedical applications, the formation of novel materials and many others. The importance of phage display platforms was recognized by awarding the Nobel Prize in 2018 ‘for the phage display of peptides and antibodies’. In contrast to many review articles concerning specific applications of phage display systems published in recent years, we present an overview of this technology, including a comparison of various display systems, their advantages and disadvantages, and examples of applications in various fields of science, medicine and the broad sense of biotechnology. Other peptide display technologies, which employ bacterial, yeast and mammalian cells, as well as eukaryotic viruses and cell-free systems, are also discussed. These powerful methods are still being developed and improved; thus, novel sophisticated tools based on phage display and other peptide display systems are constantly emerging, and new opportunities to solve various scientific, medical and technological problems can be expected to become available in the near future.

4 October 2016 in Scientific Reports
Verified
Journal Article
Open access
AJAgata Jurczak-Kurek
Agata Jurczak-Kurek
TGTomasz Gąsior
Tomasz Gąsior
BNBożena Nejman-Faleńczyk
Bożena Nejman-Faleńczyk
SBSylwia Bloch
Sylwia Bloch
ADAleksandra Dydecka
Aleksandra Dydecka
Alicja WęgrzynAlicja Węgrzyn
Alicja Węgrzyn
A large scale analysis presented in this article focuses on biological and physiological variety of bacteriophages. A collection of 83 bacteriophages, isolated from urban sewage and able to propagate in cells of different bacterial hosts, has been obtained (60 infecting Escherichia coli, 10 infecting Pseudomonas aeruginosa, 4 infecting Salmonella enterica, 3 infecting Staphylococcus sciuri, and 6 infecting Enterococcus faecalis). High biological diversity of the collection is indicated by its characteristics, both morphological (electron microscopic analyses) and biological (host range, plaque size and morphology, growth at various temperatures, thermal inactivation, sensitivity to low and high pH, sensitivity to osmotic stress, survivability upon treatment with organic solvents and detergents), and further supported by hierarchical cluster analysis. By the end of the research no larger collection of phages from a single environmental source investigated by these means had been found. The finding was confirmed by whole genome analysis of 7 selected bacteriophages. Moreover, particular bacteriophages revealed unusual biological features, like the ability to form plaques at low temperature (4 °C), resist high temperature (62 °C or 95 °C) or survive in the presence of an organic solvents (ethanol, acetone, DMSO, chloroform) or detergent (SDS, CTAB, sarkosyl) making them potentially interesting in the context of biotechnological applications.

10 February 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
GTGracja Paulina Topka-Bielecka
Gracja Paulina Topka-Bielecka
ADAleksandra Dydecka
Aleksandra Dydecka
ANAgnieszka Necel
Agnieszka Necel
SBSylwia Bloch
Sylwia Bloch
BNBożena Nejman-Faleńczyk
Bożena Nejman-Faleńczyk
Alicja WęgrzynAlicja Węgrzyn
Alicja Węgrzyn
In addition to specific antibiotic resistance, the formation of bacterial biofilm causes another level of complications in attempts to eradicate pathogenic or harmful bacteria, including difficult penetration of drugs through biofilm structures to bacterial cells, impairment of immunological response of the host, and accumulation of various bioactive compounds (enzymes and others) affecting host physiology and changing local pH values, which further influence various biological functions. In this review article, we provide an overview on the formation of bacterial biofilm and its properties, and then we focus on the possible use of phage-derived depolymerases to combat bacterial cells included in this complex structure. On the basis of the literature review, we conclude that, although these bacteriophage-encoded enzymes may be effective in destroying specific compounds involved in the formation of biofilm, they are rarely sufficient to eradicate all bacterial cells. Nevertheless, a combined therapy, employing depolymerases together with antibiotics and/or other antibacterial agents or factors, may provide an effective approach to treat infections caused by bacteria able to form biofilms.

11 December 2009 in Acta Biochimica Polonica
Verified
Journal Article
Open access
PDF file
KPKonrad Plata
Konrad Plata
ARAdriana Rosato
Adriana Rosato
Grzegorz WęgrzynGrzegorz Węgrzyn
Grzegorz Węgrzyn
Although it is estimated that 20-30% of the general human population are carriers of Staphylococcus aureus, this bacterium is one of the most important etiological agents responsible for healthcare-associated infections. The appearance of methicillin resistant S. aureus (MRSA) strains has created serious therapeutical problems. Detailed understanding of the mechanisms of S. aureus infections seems necessary to develop new effective therapies against this pathogen. In this article, we present an overview of the biochemical and genetic mechanisms of pathogenicity of S. aureus strains. Virulence factors, organization of the genome and regulation of expression of genes involved in virulence, and mechanisms leading to methicilin resistance are presented and briefly discussed.

1 January 2012
Verified
Book Chapter
Closed access
MŁMarcin Łoś
Marcin Łoś
Grzegorz WęgrzynGrzegorz Węgrzyn
Grzegorz Węgrzyn

3 May 2006 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
EPEwa Piotrowska
Ewa Piotrowska
JJJoanna Jakóbkiewicz-Banecka
Joanna Jakóbkiewicz-Banecka
SBSylwia Barańska
Sylwia Barańska
ATAnna Tylki-Szymanska
Anna Tylki-Szymanska
BCBarbara Czartoryska
Barbara Czartoryska
Grzegorz WęgrzynGrzegorz Węgrzyn
Grzegorz Węgrzyn
Mucopolysaccharidoses (MPS) are inherited, severe, progressive, metabolic disorders caused by deficiencies in different enzymes involved in degradation of glycosaminoglycans (GAGs). Although enzyme replacement therapy (ERT) has recently been available for MPS type I, and clinical trials have been performed in ERT for MPS II and MPS VI, there is little chance that this kind of treatment may be effective for neurodegenerative forms of MPS (due to inefficient delivery of enzymes to central nervous system through the blood–brain barrier), hence currently there is no effective therapy available for them. Therefore, we aim to develop an alternative therapy for these diseases. We found that genistein (4′,5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one) inhibits synthesis of GAGs considerably in cultures of fibroblasts of MPS patients (types I, II, IIIA and IIIB were tested). Prolonged cultivation of these cells in the presence of genistein resulted in reduction of GAG accumulation and normalization of cells as estimated by biochemical tests and electron microscopic analysis, respectively. As genistein inhibits kinase activity of epidermal growth factor receptor, which is required for full expression of genes coding for enzymes involved in GAG production, we propose to consider a substrate reduction therapy for MPS, which is referred to as ‘gene expression-targeted isoflavone therapy’.